ERBB2 and breast cancer: Finally, results from the Phase III SOLAR-1 study showed that the combination alpelisib–fulvestrant prolonged the PFS in postmenopausal women with PIK3CA-mutated, HR-positive, HER-2-negative advanced BC who had received endocrine therapy previously [74].